Pertussis vaccines: past, present and future in Australia.
In August 1997, a workshop was convened by the National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases to consider current issues in the use of pertussis vaccines and implications for the Australian immunisation schedule. Topics covered included the history, efficacy and reactogenicity of whole-cell and acellular vaccines and vaccine schedules. Acellular pertussis vaccine is preferred by the National Health and Medical Research Council for the primary course as well as the 18 month and 4-5 year old childhood doses. At the time of the workshop, a 3-component acellular vaccine (DTPa) had been approved (licensed) in Australia for all doses in the childhood schedule. It was the first vaccine subject to a cost-effectiveness evaluation under the new vaccine funding arrangements. Issues considered in the evaluation of the cost-effectiveness of the vaccine were discussed. These included comparative efficacy, adverse events and compliance, and the question of community as well as individual benefit from the use of the vaccine.
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Royal Alexandra Hospital for Children, Westmead, New South Wales.
P
P
McIntyre
J
J
Forrest
T
T
Heath
M
M
Burgess
B
B
Harvey
D001315:Australia; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D005544:Forecasting; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000191:economics / Q000592:standards*; D017410:Practice Guidelines as Topic; D014611:Vaccination / Q000009:adverse effects / Q000191:economics / Q000592:standards* / Q000639:trends
D010567:Pertussis Vaccine